2001
Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy
Holman R, Paddock C, Curns A, Krebs J, McQuiston J, Childs J. Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy. The Journal Of Infectious Diseases 2001, 184: 1437-1444. PMID: 11709786, DOI: 10.1086/324372.Peer-Reviewed Original ResearchConceptsRisk factorsFatal Rocky Mountain Spotted FeverRocky Mountain Spotted FeverOnset of symptomsCase fatality rateTetracycline-class antibioticsPrimary therapyClinical characteristicsOlder patientsAppropriate therapyRMSF casesNonfatal casesNational surveillanceHigh riskSpotted FeverPatientsEffective antibioticsTherapyDeathFeverAntibioticsTreatmentSymptomsFactorsDisease
1999
Hidden Mortality Attributable to Rocky Mountain Spotted Fever: Immunohistochemical Detection of Fatal, Serologically Unconfirmed Disease
Paddock C, Greer P, Ferebee T, Singleton J, McKechnie D, Treadwell T, Krebs J, Clarke M, Holman R, Olson J, Childs J, Zaki S. Hidden Mortality Attributable to Rocky Mountain Spotted Fever: Immunohistochemical Detection of Fatal, Serologically Unconfirmed Disease. The Journal Of Infectious Diseases 1999, 179: 1469-1476. PMID: 10228069, DOI: 10.1086/314776.Peer-Reviewed Original ResearchConceptsCase fatality ratioDiagnosis of RMSFIHC stainingRocky Mountain Spotted FeverLaboratory-confirmed casesAcute-phase seraTickborne infectionHidden mortalityIgM antibodiesDiagnostic titerPolymerase chain reactionIHC findingsPatient seraSerologic assaysImmunohistochemical stainingSpotted FeverImmunohistochemical detectionFatal diseasePatientsDisease controlIndirect immunofluorescenceNotifiable diseaseDiseaseUnderestimates of mortalityTissue samples